Skip to main content

Valganciclovir Disease Interactions

There are 3 disease interactions with valganciclovir.

Major

Valganciclovir (applies to valganciclovir) hematologic toxicities

Major Potential Hazard, Moderate plausibility. Applicable conditions: Pancytopenia, Bone Marrow Depression/Low Blood Counts

Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow aplasia, and aplastic anemia have been reported in patients treated with valganciclovir. The use of this agent should be avoided if the absolute neutrophil count is less than 500 cells/µL, the platelet count is less than 25,000/µ/L, or the hemoglobin is less than 8 g/dL. Complete blood counts with differential and platelet counts should be performed frequently, especially in patients that developed leukopenia after using a nucleoside analog, or in whom neutrophil counts are less than 1000 cells/µL at the beginning of treatment. Therapy with this agent should be administered with caution in patients with bone marrow depression. Increased monitoring is recommended.

References

  1. (2001) "Product Information. Valcyte (valganciclovir)." Roche Laboratories
Major

Valganciclovir (applies to valganciclovir) renal impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Dehydration

Acute renal failure has been documented in elderly patients (with or without reduced renal function), patients who receive concomitant nephrotoxic drugs, or inadequately hydrated patients. Adequate hydration, dose reduction and close monitoring of renal function are recommended when using valganciclovir in these patients. The tablet form of valganciclovir should not be used in adult patients on hemodialysis (CrCl less than 10 mL/min).

References

  1. (2001) "Product Information. Valcyte (valganciclovir)." Roche Laboratories
Moderate

Valganciclovir (applies to valganciclovir) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Monitoring is recommended when using valganciclovir in patients with hepatic impairment as the safety and efficacy of this agent has not been studied in these patients.

References

  1. (2001) "Product Information. Valcyte (valganciclovir)." Roche Laboratories

Valganciclovir drug interactions

There are 237 drug interactions with valganciclovir.

Valganciclovir alcohol/food interactions

There is 1 alcohol/food interaction with valganciclovir.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer